Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Stock Transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the conversion and sale of Class A Common Stock, along with holdings in derivative securities.

Summary

• Christopher Gibson, the CEO of Recursion Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 5th and 6th, 2025, Gibson converted 20,000 shares of Class B Common Stock into Class A Common Stock on each day.
• Simultaneously, Gibson sold 20,000 shares of Class A Common Stock on each day at prices of $7.68 and $8.12, respectively.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 1,273,156 shares of Class A Common Stock.
• Gibson also holds indirect ownership through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• Additionally, Gibson holds options to purchase a total of 3,217,967 shares of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing reflects routine transactions under a pre-arranged trading plan. There's no indication of unusual activity or significant concerns.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by the CEO could be interpreted negatively by some investors, although the pre-arranged trading plan provides context.

Risks

• Executive stock sales can sometimes create short-term downward pressure on the stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Comparing Christopher Gibson's transactions to those of executives at similar biotech companies would require analyzing their Form 4 filings.
• Generally, the use of 10b5-1 plans is a common practice among executives to manage their stock sales in a compliant manner.
• The size and frequency of these transactions would need to be benchmarked against industry peers to assess whether they are typical or unusual.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The pre-arranged nature of the sales mitigates concerns about insider information being used for personal gain.

Key Dates